FDA grants priority review to Roche's Lucentis for mCNV

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review for Roche drug Lucentis for treating myopic choroidal neovascularization (mCNV), the Swiss drugmaker said on Tuesday.